Stocks
Reata Pharmaceuticals, Inc.RETA
NASDAQHealthcareBiotechnology$172.36+0.02%
Focused on therapies for rare and serious diseases, the company develops small‑molecule drugs targeting cellular metabolism and inflammation pathways. Its pipeline has centered on treatments for neurological and kidney disorders, including an FDA‑approved therapy for Friedreich’s ataxia and investig...
Market Cap: $6.6B52W Range: $21.83 – $172.46
Congressional Interest in Reata Pharmaceuticals, Inc. (RETA)
2 members of Congress have disclosed 3 trades in Reata Pharmaceuticals, Inc. (RETA), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
2
Sells
1
Who in Congress Is Trading RETA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-04 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-12-28 | Christopher L. Jacobs | buy | $1K – $15K |